{
    "address": "Biotech Center, Arvid Wallgrens Backe 20",
    "city": "Goeteborg",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4860B119",
    "description": "Isofol Medical AB is a biotech company developing a new drug candidate; the cancer drug arfolitixorin, intended primarily for the treatment of colorectal cancer. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 12 full-time employees. The company went IPO on 2017-04-04. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The firm cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company\u2019s main shareholders are Biofol AB and Yield Life Science AB.",
    "employeeTotal": "12.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2017-04-04",
    "isin": "SE0009581051",
    "logo": "https://finnhub.io/api/logo?symbol=ISOFOL.ST",
    "marketCapitalization": 1502.094,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Isofol Medical AB (publ)",
    "phone": "46317972280.0",
    "sedol": "BF01ZZ7",
    "shareOutstanding": 145.89044,
    "state": "VASTRA GOTALANDS",
    "ticker": "ISOFOL.ST",
    "weburl": "https://isofolmedical.com/"
}